Healthcare / Medical DevicesWarsaw
$27.80
+0.10 (+0.36%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 22%
FCF escenarios
weak_data · normalized FCF $-11.1M · quality 64.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
23/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$277M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-20.8%
↓Gross Margin
84.9%
↑Debt/Equity
0.05
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2024 · 3 años de histórico normalizado
Revenue CAGR
-20.8%
FCF CAGR
—
FCF margin
-96.0%
FCF / Net income
1.43x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $24.0M · net income $-16.1M · FCF $-23.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $24.0M | $24.0M | $43.1M | $62.7M | $48.3M |
| Net Income | $-16.1M | $-16.1M | $-578000.00 | $-11.9M | $-180.6M |
| EBITDA | $-12.0M | $-12.0M | $2.2M | $29.8M | $11.1M |
| EPS | -1.62 | -1.62 | -0.06 | -2.08 | -39.73 |
| Gross Margin | 84.9% | 84.9% | 83.2% | 80.3% | 79.5% |
| Operating Margin | -67.9% | -67.9% | 1.3% | 25.6% | 25.1% |
| Net Margin | -67.0% | -67.0% | -1.3% | -18.9% | -373.6% |
| Balance Sheet | |||||
| Debt/Equity | 0.05 | 0.05 | — | 0.00 | 0.20 |
| Current Ratio | 1.30 | 1.30 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-23.0M | $-23.0M | $-11.1M | $-6.0M | $-22.4M |
| Returns | |||||
| ROE | -20.8% | -20.8% | -0.6% | -12.5% | -381.2% |
| Valuation | |||||
| EV/EBITDA | — | — | 124.08 | 1.41 | 8.37 |
| P/B | 3.60 | 3.60 | 3.27 | 0.72 | 2.01 |
| Growth & Yield | |||||
| Revenue Growth | -44.3% | -44.3% | -31.3% | 29.7% | — |
| EPS Growth | -2600.0% | -2600.0% | 97.1% | 94.8% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+7.3%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.06 → -1.62
Residual
+7.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.